Lycia Therapeutics Filed for Initial Public Offering
The biotech firm seeks capital to advance its pipeline of protein-degrading therapies following successful Phase I results.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Is the current surge in biotech IPOs a sign of a healthy innovation sector?
Lycia Therapeutics filed for an initial public offering on October 5, 2026. The company intends to use the capital to move its lead extracellular protein degrader programs through further clinical development.
Why it matters
The offering marks a significant step for Lycia, which has focused on targeting proteins for lysosomal degradation to treat chronic conditions. The capital raise follows recent Phase I data demonstrating potent reduction of targeted proteins.
Early-stage data for the candidate LCA-0061 showed a 96% mean maximum IgE reduction. The observed therapeutic effects persisted for 28 days post-dose in the majority of treated patients.
The players
Lycia Therapeutics
A biotech company focused on developing therapies that target and degrade extracellular proteins.
Carolyn Bertozzi
The co-founder of Lycia Therapeutics who established the company in 2019.
Lilly
A pharmaceutical corporation that entered a discovery deal with Lycia in 2021 and backed its 2024 Series C round.
TRex Bio
A separate biotechnology firm that has also announced plans for a $125 million public offering.
The details
Lycia utilizes a platform that targets extracellular IgE—an antibody involved in allergic responses—for lysosomal degradation, a process where cellular components are broken down in the lysosome. This mechanism allows a single degrader molecule to eliminate multiple protein targets rather than acting as a standard inhibitor. The company is also developing LCA-0321 to selectively degrade thyrotropin receptor antibodies, which are known to drive thyroid activation.
Timeline
2019: Lycia Therapeutics was co-founded by Carolyn Bertozzi.
2020: The company emerged from stealth mode with $50 million in funding.
2021: Lilly signed a discovery deal with the company.
2024: Lilly supported a $106.6 million Series C funding round.
October 5, 2026: Lycia Therapeutics filed for an initial public offering.
The Tech Race
Lycia is moving to transition from discovery-based partnerships to a public company scaling its own clinical pipeline. This IPO filing highlights the broader industry movement to capitalize on targeted protein degradation for extracellular targets.
The IPO provides the necessary runway to advance current candidates like LCA-0062 into further clinical studies. While the programs remain in the trial and development phase, the funding will determine the speed at which these therapies potentially move toward later-stage regulatory review.
The takeaway
Lycia has successfully demonstrated that its degradation platform can reach high efficacy thresholds in early clinical testing. Investors and observers should watch for the company's final valuation and the subsequent progress of the LCA-0062 candidate in upcoming IND-enabling studies.
Further reading
For more on the current landscape of clinical-stage startups, visit our Biotech section.
Live Poll
Is the current surge in biotech IPOs a sign of a healthy innovation sector?
